



Morris, Jonathan M. and Roberts, Christine L. and Bowen, Jennifer R. and Patterson, Jillian A. and Bond, Diana M. and Algert, Charles S. and Thornton, Jim and Crowther, Caroline A. (2016) Immediate delivery compared with expectant management after preterm pre-labour rupture of the membranes close to term (PPROMT trial): a randomised controlled trial. *The Lancet*, 387 (10017). pp. 444-452. ISSN 1474-547X

Access from the University of Nottingham repository:

http://eprints.nottingham.ac.uk/38555/1/PPROMT_final2.pdf

Copyright and reuse:

The Nottingham ePrints service makes this work by researchers of the University of Nottingham available open access under the following conditions.

This article is made available under the University of Nottingham End User licence and may be reused according to the conditions of the licence. For more details see:
http://eprints.nottingham.ac.uk/end_user_agreement.pdf

A note on versions:

The version presented here may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher's version. Please see the repository url above for details on accessing the published version and note that access may require a subscription.

For more information, please contact eprints@nottingham.ac.uk

Immediate delivery compared with expectant management after preterm pre-labour rupture of the membranes close to term

Jonathan Morris PhD^{1*}, Jennifer Bowen¹ MD, Jillian Patterson¹, Diana Bond¹, Charles Algert¹, Caroline Crowther^{2,3}, Jim Thornton⁴, Christine Roberts MD¹ on behalf of the PPRMT Collaboration.

1. Perinatal Research
The Kolling Institute of Medical Research
The University of Sydney
Royal North Shore Hospital
St Leonards
Australia
2. The Robinson Institute
Level 1, Queen Victoria Building
Women's & Children's Hospital
72 King William Rd
NORTH ADELAIDE SA 5006
3. Liggins Institute
The University of Auckland
85 Park Road, Grafton
Auckland NZ
4. School of Clinical Sciences.
Division of Obstetrics and Gynaecology
City Hospital.
University of Nottingham.
NOTTINGHAM UK

* Corresponding Author

Abstract

Background

Pre-labor rupture of the membranes prior to but close to term is associated with an increased risk of neonatal infection, but labor induction is associated with risks of prematurity. The balance of risks is unclear.

Aims

To test the hypothesis that a policy of inducing labor reduces neonatal infection without increasing other morbidity.

Methods

A multicenter randomized controlled trial. Participants were women with ruptured membranes prior to the onset of labor between 34+0 and 36+6 weeks, and no clinical signs of infection. The experimental group had labor induced immediately. Participants in the control group awaited the spontaneous onset of labor. The primary outcome was definite or probably neonatal infection.

Main results. The induction policy did not reduce neonatal infection. 23/923 (2.5%) intervention and 29/912 (3.2%) expectant; RR 0.8 (95% CI 0.5 – 1.3). Rates of perinatal death (3 immediate v 3 expectant), ventilation more than 24 hours 56 (6.1%) v 37 (4.1%) or infection were combined into a predefined composite neonatal morbidity outcome 73 (7.9%) immediate v 61 (6.7%) expectant RR 1.2 (0.9-1.6). However babies born to the immediate delivery group had increased rates of respiratory distress (76 (8.3%) v 47 9.2%) RR 1.6 (1.1 – 2.30 and any mechanical ventilation 114 (12.4%) v 83 (9.1%), RR 1.4 (1.0-1.8) and spent more time in newborn intensive or special care median 4 v 2 days P = 0.001.

Conclusion: In the absence of overt signs of infection or fetal compromise an expectant policy with regard to labor induction should be followed.

Prelabor rupture of the membranes (rupture of the membranes prior to the onset of labor) occurs in 20% of all births and 40% of all preterm births. At **term** there is good evidence that immediate delivery is associated with a lower incidence of maternal

infection and increased maternal satisfaction compared with expectant management, with no attendant risks of perinatal morbidity or mortality.¹ In contrast the optimal management of women with **preterm** prelabor rupture of membranes (PPROM) prior to 37 weeks, is not clear.²

There is substantial practice variation internationally particularly in women who present near term, beyond 34 weeks gestation.³⁻⁵ Planned immediate delivery is both practiced⁴ and recommended based upon conclusions that “compared with expectant management, induction of labor is associated with shorter latency to delivery and lower risk for maternal infection without excess risk for cesarean delivery”.⁶ This is despite recognition by professional bodies such as the American and British Colleges of Obstetricians and Gynecologists that such recommendations are “based on limited and inconsistent scientific evidence.”^{7,8}

Unlike PROM at term, pre-term PROM, therefore, continues to pose a clinical dilemma. The risks from delay such as placental abruption, ascending infection, intrapartum fetal distress and cord prolapse^{9,10} need to be balanced against the risks of iatrogenic prematurity from immediate delivery. At extreme preterm gestations (less than 30 weeks), in the absence of established infection or maternal or fetal compromise, there is unanimity that expectant management is desirable⁵ because the risk of neonatal mortality, intraventricular hemorrhage, hyaline membrane disease and necrotizing enterocolitis. However, these risks are reduced as the gestational age extends towards term.¹¹ Recommendations for immediate delivery following preterm ruptured membranes close to term require grounding in good clinical evidence as even mild prematurity is associated with a significant health burden both in the short and long term.¹² We undertook an international multicentre randomized controlled trial to establish the optimal management of birth following preterm premature rupture of the membranes close to term (PPROMT): comparing immediate delivery with expectant management, the PPRoMT Trial (ISRCTN44485060)

Methods

Recruitment

Eligible women were aged over 16 with a singleton pregnancy and clinically suspected ruptured membranes between 34⁰ weeks and 36⁶ weeks gestation. Women who presented with ruptured membranes earlier in pregnancy became eligible if they reached 34 weeks gestation. Exclusion criteria were established labor, chorioamnionitis, meconium staining, or any other contraindication to continuing the pregnancy. Group B streptococcus (GBS) vaginal colonization was not an exclusion criterion. The study took place in 65 centers in 11 countries (Australia, New Zealand, Argentina, South Africa, Brazil, UK, Norway, Egypt, Uruguay, Poland, Romania) between May 2004 and June 2013. All participating centers had the facilities for mothers and babies born at 34 weeks, including respiratory support. The study was approved by the institutional ethics review boards of each clinical site. All participants gave written informed consent before enrollment.

Protocol¹³

Eligible women were identified by a local research coordinator or clinical staff, provided the trial information sheet, and after written informed consent entry details were recorded on a trial entry form and they were randomized via a central telephone service using a computer generated randomization schedule in a 1:1 ration in balanced blocks of variable size, stratified by center. An automated process collected basic patient identifying information and, after confirmation that entry into the study was sought, a study number and the treatment allocation was provided.

Participants were randomly assigned to immediate delivery or expectant management. The former group had delivery scheduled as close to randomization as possible and preferably within 24 hours. The mode of birth was determined by usual obstetric indications. For women randomized to expectant management, birth occurred after spontaneous labor, at term or when the attending clinician felt that birth was mandated according according to the usual indications. For much of the recruitment period antibiotics were considered best practice in the presence of preterm prelabor ruptured membranes¹⁴ and these were prescribed according to local protocols. Placental histology was encouraged but not uniformly requested.

Study outcomes

The primary outcome was the incidence of either definite or probable neonatal sepsis determined by a central adjudication committee masked to the treatment allocation.

Definite systemic neonatal infection (definite sepsis) was defined a positive culture of a known pathogen from blood or cerebrospinal fluid (CSF), the baby treated with antibiotics for 5 or more days (or died before 5 days), and the presence of clinical signs of infection. For organisms of low virulence and/or high likelihood of skin contamination of the blood culture, such as coagulase negative staphylococcus, both a positive blood culture and an abnormal full blood count or abnormal C-Reactive Protein (CRP) were required. An abnormal full blood count (FBC) included abnormal white cell count [WCC] $<5 \times 10^9 /L$ or $>30 \times 10^9 /L$, platelet count $<100,000$, neutrophil count $<1.5 \times 10^9 /L$ or raised immature to total neutrophil ratio (I:T ratio >0.2).^{15,16} A CRP $>10\text{mg/L}$ was considered abnormal.^{17,18}

Clinical signs of infection included respiratory distress (requiring ventilation, continuous positive airway pressure or supplemental oxygen for more than one hour), apnea, lethargy, abnormal level of consciousness, circulatory compromise (including hypotension, poor perfusion, need for inotropic support or volume expansion) and/or temperature instability (temperature $<36^\circ\text{C}$ or $\geq 38^\circ\text{C}$).

Probable neonatal infection was defined as the presence of clinical signs where the baby was treated with antibiotics for 5 or more days together with one or more of: an abnormal FBC; abnormal CRP; positive GBS antigen on bladder tap urine, blood or CSF; elevated CSF white cell count ⁵ (CSF WCC $>100 \times 10^6/L$); growth of a known virulent pathogen (eg GBS, E.coli, Listeria) from surface swab; or a histologic diagnosis of pneumonia in an early neonatal death.

Pre-specified secondary neonatal outcomes^{13,19} included composite neonatal morbidity (sepsis, mechanical ventilation >24 hours, stillbirth or neonatal death), respiratory distress, perinatal mortality, pneumonia, mechanical ventilation (intermittent positive pressure ventilation, continuous positive airway pressure or high frequency ventilation) for greater than 24 hours, duration of stay in a neonatal intensive or special care unit, duration of stay in hospital, birth weight, Apgar score ≤ 7 at 5 minutes,

antibiotics in the first 48 hours, lumbar puncture, circulatory compromise requiring arterial line, fluid bolus or inotropic support, and receiving breast milk at discharge (exclusive or mixed feeding). Neonatal outcomes were obtained from diagnoses reported by the attending clinician in the medical records, and collected for 28 days or until discharge .

Secondary maternal outcomes included antepartum or intrapartum hemorrhage, antepartum or postpartum thrombosis, cord prolapse, postpartum treatment with antibiotics, intrapartum fever (pyrexia $\geq 38.5^{\circ}\text{C}$), postpartum hemorrhage (>1000 ml), mode of delivery, onset of labor and duration of hospitalization (total days from randomization to delivery, and from delivery to discharge or transfer).

Chorioamnionitis was a trial entry exclusion criteria but this outcome is reported among the women with expectant management. Placental swabs and histology were also collected if available.

As far as I can see you've not reported the following maternal secondary outcomes from trial registration.

2.3. Post-partum fever

2.8. Assisted vaginal delivery

2.9. Maternal satisfaction

2.10. Views of care

time to fully establish breast feeding

2.13. Maternal emotional wellbeing

2.14. Anxiety and depression

Other measures:

Where time of day of randomization or PPRM were missing, the hours from PPRM to randomization was imputed as the difference in days, plus 9 hours (the median for non-missing participants). Only cultures from vaginal swabs taken between PPRM and randomization were assessed and findings of 'normal vaginal flora' and 'lactobacilli' were classified as negative. All other patient characteristics were reported by the participants at trial entry or collected from medical records.

Statistical Analysis

A sample size of 1812 (906 patients per arm) was necessary to detect a reduction in neonatal sepsis of 5% in the expectantly managed arm compared with 2.5% in the immediate delivery arm with a two-sided 5% significance level and a power of 80%. One interim analysis was performed in February 2010 by the independent data monitoring committee, prior to submission for further funding, who reviewed the findings (506 women had been recruited) and recommended that the study continue. A difference of at least three standard deviations in interim analysis of a major endpoint was needed to justify stopping the trial.

All analyses were by intention-to-treat. No participants were excluded from the primary intention to treat analysis due to protocol violations. The primary outcome was calculated as event numbers and percentages, by treatment allocation. Effect measures (relative risk [RR]) were calculated with a 95% confidence interval (95% CI), using expectant management as the reference group. Comparison of mean birthweight was performed using a t-test. Comparisons of maternal and infant length of stay (days) were performed using non-parametric Wilcoxon Mann-Whitney tests. There was no imputation for missing outcome data. Participants with missing data were excluded from calculation of secondary outcomes, with the numbers missing reported by group.

Predefined criteria for whether adjusted analyses were required¹⁹ were a relative difference of >15% between arms in the median duration from PROM to randomization; and/or a >3 day difference in median gestational age at randomization. If either had been met, adjusted logistic regression would have been performed. No adjustment to the level of statistical significance was made for multiple comparisons.

Pre-specified subgroup analyses for the primary outcome of neonatal sepsis included time from PPRM until randomization (<48 hours, ≥48 hours); gestational week of PPRM (<34 weeks, ≥34 weeks); vaginal swab culture result (GBS, other abnormal flora); and antibiotic administration at randomization.

Results

between May 2004 and June 2013 a total of 1839 women were recruited into the study. Figure 1 demonstrates the flow of participants through the study. Thirteen women in

the immediate delivery arm did not receive the allocated intervention compared with only one protocol violation in the expectant management arm. The primary outcome was assessed for 1835 (99.8%) of those women randomized (immediate delivery 923; expectant management 912).

The baseline characteristics of the two arms were similar (Table 1). The median gestational age at randomization in each arm was 247 days and the median time in hours from ruptured membranes to randomization was 30.4 hours in the immediate delivery arm and 26.4 hours (13.4% lower) in the expectantly managed arm so no adjusted analyses were performed. Figure 2 shows the difference in time between randomization and delivery for the two arms of the trial.

At the time of randomization, approximately 40% of women in each arm had received antenatal steroids and 86% received antibiotics (Table 1). Any antibiotics prior to delivery were prescribed for 852 (92.3%) women in the immediate delivery arm and 844 (92.5%) in the expectant management arm. In the expectant management arm 688 (73.2%) women were managed in hospital and the remainder were sent home between randomization and delivery.

Women randomized to expectant management were more likely to deliver following the spontaneous onset of labor, have a cephalic presentation at birth and deliver at a later gestation than those allocated to immediate delivery (Table 2). Six women randomized to “immediate delivery” delivered after 36 weeks including 5 who were found not to have PROM after randomization and 1 who self-discharged from the enrolling hospital and birthed later.

The primary outcome of definite or probable neonatal sepsis occurred in 23 (2.5%) of the 923 neonates whose mothers were assigned to immediate delivery and 29 (3.2%) of the 912 neonates whose mothers were assigned expectant management (RR 0.8; 95% CI, 0.5 to 1.3) (Table 3). There was no significant difference in the composite measure of mortality and neonatal morbidity including sepsis, ventilation >24 hours and perinatal death, occurring in 73 (7.9%) of those allocated immediate delivery and 61 (6.7%) of those managed expectantly. However, those babies born following immediate delivery

had significantly lower birthweights, increased risk of respiratory distress and mechanical ventilation, and spent more time in newborn intensive care or special care nursery (Table 4).

There were six perinatal deaths, three in each arm of the trial. Among women randomized to immediate delivery the deaths were from: sudden infant death syndrome (SIDS) (4 weeks of age); congenital abnormality (3 weeks of age); and fetal death at 35 weeks gestation associated with acute suppurative chorioamnionitis based on the autopsy report.. Among women randomized to expectant management the deaths were from: SIDS (5 weeks of age); a congenital abnormality (12 weeks of age); and one of unknown cause (at 24 hours of age).

Expectant management was associated with a greater likelihood of antepartum hemorrhage (2.9% vs 5%) and intrapartum fever (0.8% vs 2.1%) (Table 3). Cesarean delivery occurred in 239 (25.9%) women allocated to immediate delivery compared with 169 (18.5%) of those women allocated to expectant care (RR 1.4; 95% CI, 1.2 to 1.7). Fifty six (6.1%) women in the expectant management arm were delivered because of choriamnionitis subsequent to randomization.

Neonatal sepsis was not significantly associated with immediate delivery or expectant management in any of the strata of the prespecified subgroup analyses (Table 4). Immediate delivery had no influence on sepsis regardless of the gestational age at PPRM, the duration of PPRM or the administration of antibiotics at the time of PPRM. Of women managed expectantly 191 (?%) women had an abnormal organism isolated from the swab including 78 with GBS. In those allocated to immediate delivery 190 (?%) women had a swab collected that isolated an abnormal organism, including 83 with GBS. For women allocated to immediate delivery neonatal sepsis occurred in 2.1% of neonates born to women who had a positive culture on their vaginal swab compared with 4.7% in those born to mothers with a positive culture and managed expectantly (RR 0.4; 95% CI, 0.1 to 1.4).

Discussion

This trial demonstrates that for women with ruptured membranes between 34⁰ and 36⁶

weeks gestation carrying a single fetus and no contraindication for expectant management, immediate delivery increased neonatal complications with no clinically significant decrease in neonatal sepsis. Therefore in contrast to recent guideline recommendations,^{6,8} we advocate that expectant management is preferred to immediate delivery in women with ruptured membranes close to term.

This is the largest study to compare these two forms of currently accepted management. Older studies that included women with PROM at preterm gestations were unable to demonstrate any reduction in neonatal sepsis or differences in neonatal morbidity² and two underpowered studies with inclusion criteria similar to the PPRMOT Trial published while the present study was ongoing also reported that immediate delivery did not reduce neonatal sepsis.^{20 21} They concluded that there was no increase in neonatal morbidity or cesarean delivery. The PPRMOT Trial is the most adequately powered study to demonstrate that immediate delivery does not reduce neonatal sepsis but does increase the likelihood of several aspects of early neonatal morbidity including respiratory distress, mechanical ventilation and duration of stay in newborn intensive care. This has significant implications for practice and widespread adoption of expectant management following ruptured membranes close to term is likely to have significant resource and economic benefits.

The adoption of the practice of immediate delivery, advocated in recent guidelines is predicated on the fact that disability free survival rates following birth are very high. However, there is increasing concern about the risks of adverse outcome for late preterm neonates, with studies identifying an increased risk of neonatal morbidity²², rehospitalisation in early childhood²³ and academic difficulties in children at school age²⁴. These risks are thought to be associated with both gestational age and biological factors associated with the preterm birth, including PPRM²⁵, however, immediate delivery does not appear to improve outcomes in preterm neonates and may exacerbate the risks of prematurity because of birth in the absence of labor and earlier gestational age. Although expectant management in a potentially hostile intrauterine environment should be avoided, in a mother who remains well, with no evidence of clinical chorioamnionitis, expectant management provides an opportunity for spontaneous labor to develop and for adaptive changes to occur in the neonate resulting in decreased

risk of neonatal respiratory illness ²⁶. For some neonates, expectant management may also result in delivery at a substantially older gestational age. These factors may in turn result in a decrease in neonatal morbidity, decreased separation of mother and baby, improved breast feeding rates and a reduction in risk of adverse childhood outcomes.

In circumstances such as PPRM, where the risks and benefits of immediate delivery compared with expectant management have been unclear, policy makers have called on clinicians to develop evidence-based data to assess risk/benefit ratios for diagnosis specific indications for delivery at late-preterm gestations ²²

The PPROMT trial is sufficiently large to provide evidence of the risks and benefits associated with immediate delivery following PPRM. Risks identified with immediate delivery include an increase in respiratory distress requiring ventilator support for the baby, an increase in duration of admission to a neonatal intensive care or special care nursery and an increased likelihood of cesarean for the mother. On the other hand expectant management does not appear to significantly increase the likelihood of neonatal sepsis, but resulted in a lengthier hospital stay for the mother as most were managed as inpatients. This is important information that care providers can discuss with women regarding best practice in this clinical situation.

Although expectant management was provided according to each hospital's current usual care, 75% of women were managed as inpatients and over 90% received antibiotics prior to delivery. Our findings suggest that expectant management should include careful monitoring for/heightened surveillance of fever, symptoms of chorioamnionitis and antepartum hemorrhage.

In addition to its size, the strengths of the PPROMT trial include the fact that it reflects contemporary maternity practice, was centrally randomized, had near complete follow up and was conducted across a range of international settings making the results widely generalizable. Many previous studies evaluating the management of ruptured membranes were small and performed prior to the widespread implementation of

maternal antibiotic administration to prolong latency and reduce short term morbidity, including neonatal infection.^{14,27-32} The PPRMT Trial results, together with the results of the recent PPROMEXIL studies,^{20,21} suggest there are benefits from expectant management without incurring significant risk of harms. It may be possible that there are groups of women who benefit from immediate delivery. Contrary to a recent report,³³ our findings were that immediate delivery did not confer benefit on the women in whom Group B Streptococcus was isolated from the genital tract. There are opportunities to explore such risk factors further to identify specific indications for which immediate delivery is appropriate by performing an individual patient data meta-analysis of all those who participated in PPRMT and PPROMEXIL.

Conclusion

Contrary to the advice of many current guidelines, the PPRMT Trial found that expectant management does not increase the risk of neonatal sepsis but reduces neonatal morbidity in neonates of women who present with ruptured membranes close to term and that this should be advocated as best practice internationally.

Acknowledgements:

This study was funded by the Australian NHMRC Project Grants (IDs: 358378 and 1009898). Start up funds were provided by the Women's and Children's Hospital Foundation, Adelaide. Bridging support was provided by The University of Sydney.

Additionally the PPRMT team acknowledges the support of the UK National Institute for Health Research, through the Comprehensive Clinical Research Network.

References

1. Hannah ME, Ohlsson A, Farine D, et al. Induction of labor compared with expectant management for prelabor rupture of the membranes at term. TERMPROM Study Group. *The New England journal of medicine* 1996;334:1005-10.
2. Buchanan SL, Crowther CA, Levett KM, Middleton P, Morris J. Planned early birth versus expectant management for women with preterm prelabour rupture of membranes prior to 37 weeks' gestation for improving pregnancy outcome. *The Cochrane database of systematic reviews* 2010:CD004735.
3. Ramsey PS, Nuthalapaty FS, Lu G, Ramin S, Nuthalapaty ES, Ramin KD. Contemporary management of preterm premature rupture of membranes (PPROM): a survey of maternal-fetal medicine providers. *American journal of obstetrics and gynecology* 2004;191:1497-502.

4. Healy AJ, Veille JC, Sciscione A, McNutt LA, Dexter SC, Society of Maternal-Fetal M. The timing of elective delivery in preterm premature rupture of the membranes: a survey of members of the Society of Maternal-Fetal Medicine. *American journal of obstetrics and gynecology* 2004;190:1479-81.
5. Buchanan S, Crowther C, Morris J. Preterm prelabour rupture of the membranes: a survey of current practice. *The Australian & New Zealand journal of obstetrics & gynaecology* 2004;44:400-3.
6. American College of Obstetrics and Gynecology. ACOG Practice Bulletin No. 139: Premature rupture of membranes. *Obstetrics and gynecology* 2013;122:918-30.
7. American College of Obstetrics and Gynecology. ACOG Practice Bulletin No. 80: premature rupture of membranes. Clinical management guidelines for obstetrician-gynecologists. *Obstetrics and gynecology* 2007;109:1007-19.
8. Gynaecologists RCoOa. Preterm Prelabour Rupture of Membranes (Green-top 44). 2010;<http://www.rcog.org.uk/womens-health/clinical-guidance/preterm-prelabour-rupture-membranes-green-top-44> (accessed June 2014).
9. Alexander JM, Cox SM. Clinical course of premature rupture of the membranes. *Seminars in perinatology* 1996;20:369-74.
10. Gonen R, Hannah ME, Milligan JE. Does prolonged preterm premature rupture of the membranes predispose to abruptio placentae? *Obstetrics and gynecology* 1989;74:347-50.
11. Morris JM, Algert CS, Falster MO, et al. Trends in planned early birth: a population-based study. *American journal of obstetrics and gynecology* 2012;207:186 e1-8.
12. Teune MJ, Bakhuizen S, Gyamfi Bannerman C, et al. A systematic review of severe morbidity in infants born late preterm. *American journal of obstetrics and gynecology* 2011;205:374 e1-9.
13. Morris JM, Roberts CL, Crowther CA, Buchanan SL, Henderson-Smart DJ, Salkeld G. Protocol for the immediate delivery versus expectant care of women with preterm prelabour rupture of the membranes close to term (PPROMT) Trial [ISRCTN44485060]. *BMC Preg Childbirth* 2006;6:9.
14. Kenyon S, Boulvain M, Neilson JP. Antibiotics for preterm rupture of membranes. *The Cochrane database of systematic reviews* 2013;12:CD001058.
15. Guida JD, Kunig AM, Leef KH, McKenzie SE, Paul DA. Platelet count and sepsis in very low birth weight neonates: is there an organism-specific response? *Pediatrics* 2003;111:1411-5.
16. Ottolini MC, Lundgren K, Mirkinson LJ, Cason S, Ottolini MG. Utility of complete blood count and blood culture screening to diagnose neonatal sepsis in the asymptomatic at risk newborn. *Pediatr Infect Dis J* 2003;22:430-4.
17. Philip AG, Hewitt JR. Early diagnosis of neonatal sepsis. *Pediatrics* 1980;65:1036-41.
18. Philip AG, Mills PC. Use of C-reactive protein in minimizing antibiotic exposure: experience with infants initially admitted to a well-baby nursery. *Pediatrics* 2000;106:E4.
19. Algert CS, Lain S, Patterson J. The Preterm Prelabour Rupture of Membranes close to Term (PPROMT) Trial: statistical analysis plan. Sydney, Australia <http://ses.library.usyd.edu.au/handle/2123/10336> (Accessed June 2014)2014.
20. van der Ham DP, van der Heyden JL, Opmeer BC, et al. Management of late-preterm premature rupture of membranes: the PPROMEXIL-2 trial. *American journal of obstetrics and gynecology* 2012;207:276 e1-10.

21. van der Ham DP, Vijgen SM, Nijhuis JG, et al. Induction of labor versus expectant management in women with preterm prelabor rupture of membranes between 34 and 37 weeks: a randomized controlled trial. *PLoS medicine* 2012;9:e1001208.
22. Raju TN, Higgins RD, Stark AR, Leveno KJ. Optimizing care and outcome for late-preterm (near-term) infants: a summary of the workshop sponsored by the National Institute of Child Health and Human Development. *Pediatrics* 2006;118:1207-14.
23. Lain SJ, Nassar N, Bowen JR, Roberts CL. Risk factors and costs of hospital admissions in first year of life: a population-based study. *J Pediatr* 2013;163:1014-9.
24. McGowan JE, Alderdice FA, Holmes VA, Johnston L. Early childhood development of late-preterm infants: a systematic review. *Pediatrics* 2011;127:1111-24.
25. Brown HK, Speechley KN, Macnab J, Natale R, Campbell MK. Neonatal morbidity associated with late preterm and early term birth: the roles of gestational age and biological determinants of preterm birth. *Int J Epidemiol* 2014;43:802-14.
26. Lee J, Seong HS, Kim BJ, Jun JK, Romero R, Yoon BH. Evidence to support that spontaneous preterm labor is adaptive in nature: neonatal RDS is more common in "indicated" than in "spontaneous" preterm birth. *J Perinat Med* 2009;37:53-8.
27. Nelson LH, Meis PJ, Hatjis CG, Ernest JM, Dillard R, Schey HM. Premature rupture of membranes: a prospective, randomized evaluation of steroids, latent phase, and expectant management. *Obstetrics and gynecology* 1985;66:55-8.
28. Spinnato JA, Shaver DC, Bray EM, Lipshitz J. Preterm premature rupture of the membranes with fetal pulmonary maturity present: a prospective study. *Obstetrics and gynecology* 1987;69:196-201.
29. Mercer BM, Crocker LG, Boe NM, Sibai BM. Induction versus expectant management in premature rupture of the membranes with mature amniotic fluid at 32 to 36 weeks: a randomized trial. *American journal of obstetrics and gynecology* 1993;169:775-82.
30. Cox SM, Leveno KJ. Intentional delivery versus expectant management with preterm ruptured membranes at 30-34 weeks' gestation. *Obstetrics and gynecology* 1995;86:875-9.
31. van Heerden J, Steyn DW. Management of premature rupture of the membranes after 34 weeks' gestation -- early versus delayed induction of labour. *South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde* 1996;86:264-8.
32. Naef RW, 3rd, Allbert JR, Ross EL, Weber BM, Martin RW, Morrison JC. Premature rupture of membranes at 34 to 37 weeks' gestation: aggressive versus conservative management. *American journal of obstetrics and gynecology* 1998;178:126-30.
33. Tajik P, van der Ham D, Zafarmand M, et al. Using vaginal Group B Streptococcus colonisation in women with preterm premature rupture of membranes to guide the decision for immediate delivery: a secondary analysis of the PPRMEXIL trials. *BJOG : an international journal of obstetrics and gynaecology* 2014.

Figure 1: Randomization and follow-up of study participants




Figure 2: Time from randomization until birth, by treatment assignment




Table 1 Maternal and pregnancy factors at or before time of randomization, by treatment assignment

	Immediate delivery N=923 n (%)	Expectant management N=912 n (%)
Rupture of membranes		
<28 ⁰ weeks	13 (1.4)	14 (1.5)
28 ⁰ to 29 ⁶ weeks	14 (1.5)	9 (1.0)
30 ⁰ to 31 ⁶ weeks	21 (2.3)	34 (3.7)
32 ⁰ to 33 ⁶ weeks	161 (17.4)	129 (14.1)
34 ⁰ to 34 ⁶ weeks	212 (23.0)	225 (24.7)
35 ⁰ to 35 ⁶ weeks	279 (30.2)	271 (29.7)
36 ⁰ to 36 ⁶ weeks	223 (24.2)	230 (25.2)
Randomised		
34 ⁰ to 34 ⁶ weeks	363 (39.3)	355 (38.9)
35 ⁰ to 35 ⁶ weeks	278 (30.1)	292 (32.0)
36 ⁰ to 36 ⁶ weeks	282 (30.6)	265 (29.1)
PPROM ≥ 48 hours before randomization	328 (35.5)	302 (33.1)
Maternal age (years) (mean, std.dev.)	27.9 (6.2)	28.0 (6.2)
Previous pregnancies		
0	426 (46.2)	430 (47.1)
1	232 (25.1)	241 (26.4)
≥ 2	265 (28.7)	241 (26.4)
Cephalic presentation	880 (95.3)	876 (96.1)
Previous cesarean delivery	93 (10.1)	85 (9.3)
Previous PPRM or preterm delivery	137 (14.8)	125 (13.7)
Previous stillbirth or neonatal death	21 (2.3)	24 (2.6)
Pregnancy hypertension (onset ≥ 20 weeks)	24 (2.6)	33 (3.6)
Gestational diabetes	50 (5.4)	48 (5.3)
Antenatal urinary tract infection	99 (10.7)	87 (9.5)
Antibiotics given*		
intravenous (+/- oral)	321 (34.8)	286 (31.4)
oral only	473 (51.2)	500 (54.8)
Steroids given	383 (41.5)	354 (38.8)
Positive culture from a vaginal swab†		
any positive culture	190 (20.6)	191 (20.9)
Group B streptococcus positive	83 (9.0)	78 (8.6)

* antibiotics at randomization or in preceding 48 hours

† culture resulting from vaginal swab after PPRM and at or before randomization

Missing data (#immediate delivery, # expectant management): Previous CS (1,1); Previous PPRM (0,1);
Previous stillbirth (0,1); Antibiotics (2,4); Positive culture (223,230)

Table 2 Labor characteristics, by treatment assignment

Labor characteristic	Immediate delivery N=920 n (%)	Expectant management N=915 n (%)	P value
<i>Onset of labor</i>			
Spontaneous	180 (19.5)	549 (60.2)	<0.0001*
Induced	647 (70.1)	310 (34.0)	
Pre-labor cesarean	96 (10.4)	53 (5.8)	
<i>Cephalic presentation at birth</i>	49 (5.3)	33 (3.6)	<0.0001†
<i>Gestational age at birth</i>	315 (34.1)	161 (17.7)	
34 weeks	273 (29.6)	268 (29.4)	
35 weeks	306 (33.2)	295 (32.3)	
36 weeks	23 (2.5)	174 (19.1)	
37 weeks	1 (0.1)	7 (0.8)	
38 weeks	1 (0.1)	2 (0.2)	
39 weeks	1 (0.1)	5 (0.5)	
40 weeks	3 (0.3)	0 (0.0)	
41 weeks	180 (19.5)	549 (60.2)	<0.0001*

* P value for difference in mode of delivery across treatment groups

† Wilcoxon P value for test of null hypothesis of no difference in distribution between treatment arms

Table 3 Infant and maternal outcomes by treatment assignment

Infant outcome	Immediate delivery n (%)	Expectant management n (%)	Relative risk RR (95% CI)
Neonatal sepsis	23/ 923 (2.5)	29/ 912 (3.2)	0.8 (0.5, 1.3)
Secondary infant outcomes			
Composite of neonatal morbidity (sepsis, ventilation ≥24 hours or death)	73/ 923 (7.9)	61/ 911 (6.7)	1.2 (0.9, 1.6)
Perinatal death	3/ 923 (0.3)	3/ 910 (0.3)	1.0 (0.2, 4.9)
Respiratory distress syndrome	76/ 919 (8.3)	47/ 910 (5.2)	1.6 (1.1, 2.3)
Pneumonia	3/ 919 (0.3)	4/ 910 (0.4)	0.7 (0.2, 3.3)
Any mechanical ventilation (CPAP or ETT)	114/ 923 (12.4)	83/ 912 (9.1)	1.4 (1.0, 1.8)
mechanical ventilation for ≥ 24 hours	56/ 923 (6.1)	37/ 912 (4.1)	1.5 (1.0, 2.2)
Mean birthweight in grams (SD)	2574.7 (400.3)	2673.2 (405.5)	<.0001
SGA <10 th percentile size	32/ 922 (3.5)	35/ 906 (3.9)	0.9 (0.6, 1.4)
Apgar score <7 at 5 minutes	15/ 918 (1.6)	18/ 906 (2.0)	0.8 (0.4, 1.6)
Antibiotics in first 48 hours	422/ 920 (45.9)	398/ 910 (43.7)	1.0 (0.9, 1.2)
Lumbar puncture	33/ 921 (3.6)	38/ 911 (4.2)	0.9 (0.5, 1.4)
Circulatory compromise	11/ 921 (1.2)	13/ 910 (1.4)	0.8 (0.4, 1.9)
Infant days in hospital*	6.0 (3.0, 10.0)	4.0 (3.0, 8.0)	<.0001
Days in SCN/NICU†*	4.0 (0.0, 10.0)	2.0 (0.0, 7.0)	<.0001
Receiving breast milk at discharge	695/ 883 (78.7)	712/ 877 (81.2)	1.0 (0.9, 1.0)
Secondary maternal and pregnancy outcomes			
Antepartum hemorrhage	27/ 923 (2.9)	46/ 912 (5.0)	0.6 (0.4, 0.9)
Cord prolapse	3/ 923 (0.3)	2/ 912 (0.2)	1.5 (0.2, 8.8)
Intrapartum fever	7/ 923 (0.8)	18/ 912 (2.0)	0.4 (0.2, 0.9)
Postpartum antibiotics	151/ 923 (16.4)	180/ 912 (19.7)	0.8 (0.7, 1.0)
Postpartum hemorrhage (PPH)	29/ 803 (3.6)	27/ 782 (3.5)	1.0 (0.6, 1.8)
Maternal duration of hospitalization*	5.0 (3.0, 7.0)	6.0 (4.0, 9.0)	<.0001
Cesarean delivery (CD)	239/ 923 (25.9)	169/ 912 (18.5)	1.4 (1.2, 1.7)
CD following spontaneous labor	24/ 180 (13.3)	54/ 549 (9.8)	1.4 (0.9, 2.1)
CD following labor induction	119/ 647 (18.4)	62/ 310 (20.0)	0.9 (0.7, 1.2)
Pre-labor cesarean delivery	96/ 923 (10.4)	53/ 912 (5.8)	1.8 (1.3, 2.5)
Missing but pre-specified secondary outcomes			
2.3. Post-partum fever			
2.8. Assisted vaginal delivery			
2.9. Maternal satisfaction			
2.10. Views of care			
time to fully establish breast feeding			
2.13. Maternal emotional wellbeing			

2.14. Anxiety and depression

CPAP continuous positive pressure ventilation; ETT endotracheal tube; SD standard deviation; SGA small for gestational age; SCN special care nursery; NICU neonatal intensive care

* median and interquartile range reported for duration of admission, Wilcoxon P value for test of null hypothesis of no difference in distribution between treatment arms

† days in a Special Care Nursery and/or Neonatal Intensive Care Unit

Missing data (#immediate delivery, # expectant management): composite (0,1); perinatal death (0,2); RDS (4,2); Pneumonia (4,2); birthweight (0,2); SGA (1,6), Apgar (5,6); antibiotics (3,2); lumbar puncture (2,1); Circulatory compromise (2,2) infant days in hospital (2,3); days in SCN/NICU (1,2); Breast milk at discharge (40,35); PPH (120,130); maternal duration of hospitalization (2,2)

Table 4: Pre-specified subgroup analyses for neonatal sepsis by treatment assignment

Infant outcome	Immediate delivery Sepsis n/N (%)	Expectant management Sepsis n/N (%)	Neonatal sepsis RR (95% CI)
Duration from PPROM to randomization			
< 48 hours	19/ 595 (3.2)	18/ 610 (3.0)	1.1 (0.6, 2.0)
≥ 48 hours	4/ 328 (1.2)	11/ 302 (3.6)	0.3 (0.1, 1.0)
Gestation of PPROM			
before 34 weeks	4/ 209 (1.9)	7/ 186 (3.8)	0.5 (0.2, 1.7)
≥ 34 weeks	19/ 714 (2.7)	22/ 726 (3.0)	0.9 (0.5, 1.6)
Vaginal culture after PPROM*			
GBS	3/ 83 (3.6)	3/ 78 (3.8)	0.9 (0.2, 4.5)
other organism	1/ 107 (0.9)	6/ 113 (5.3)	0.2 (0.0, 1.4)
negative or no culture collected	19/ 733 (2.6)	20/ 721 (2.8)	0.9 (0.5, 1.7)
Vaginal culture after PPROM*			
Any culture positive	4/ 190 (2.1)	9/ 191 (4.7)	0.4 (0.1, 1.4)
Negative or no culture collected	19/ 733 (2.6)	20/ 721 (2.8)	0.9 (0.5, 1.7)
Maternal antibiotics at randomization†			
Yes	20/ 795 (2.5)	24/ 787 (3.0)	0.8 (0.5, 1.5)
No	3/ 127 (2.4)	5/ 122 (4.1)	0.6 (0.1, 2.4)

* culture from vaginal swab after PPROM and at or before randomization

† antibiotics at randomization or in preceding 48 hours

The PPROMT Collaborators

ARGENTINA (207): Hospital Penna, *M Bertin, J Castaldi* (113); Hospital Nacional Posadas, *G Olsen, C Pagano, M Palermo, I Ribola, E Romero, C Siamarella, D Varela, S Varela*, (68); J.R.Vidal Hospital, *D Aguirre, E Morales* (26); **AUSTRALIA (972): (ACT)** The Canberra Hospital, *D Ellwood, C Fowler* (18); **(NSW)** Campbelltown Hospital, *R Dalal, J Song* (20); Gosford Hospital, *G Kemball, J Knox* (9); Hornsby-Ku-ring-gai Hospital, *J Keogh, T Nanda, J Sim* (9); John Hunter Hospital, *A Carlin, W Giles, A Wright* (59); Liverpool Hospital, *J Ebner, J Smoleniec, J White* (30); Nepean Hospital, *T Codner, S Downward, C Dunn, D Hansen, E Masson, M Peek, S Sellar* (85); Royal Hospital for Women, *A Lainchbury, R Reid, A Shand, A Welsh* (20); Royal North Shore Hospital, *J Milligen, J Morris, K Rickard, R Sau-Harvey, J Sedgley, K White-Matthews* (82); Royal Prince Alfred Hospital, *J Hyett, H Phipps* (35); St George Public Hospital, *G Davis, L Roberts* (27); Westmead Hospital, *I Alahakoon, M Barkho, S Heath, L Luck, T McCreanor, T McGee* (77); Wollongong Hospital, *W Davis, A Goodfellow* (32); **(QLD)** Caboolture Hospital, *K Brown, F Hills, M Ratnapala, A Whittaker* (14); Gold Coast Hospital, *D Charters, J Connell, L Dunstan, M Johnson, D Nyariri, H Safa, J Toohill, E Yeung* (22); Ipswich Hospital, *A Green, K Mahomed* (27); Mater Mothers' Hospital, *G Gardener, S Jenkins-Marsh, J MacPhail, A Peacock, A Tremellen* (57); Mackay Base Hospital, *K Braniff, J Collins, F Patel* (8); Redcliffe Hospital, *A Kothari, M Shalcross* (15); Royal Brisbane & Women's Hospital, *P Colditz, L McKeown, M Pritchard* (26); The Townsville Hospital, *C Boniface, C Davies, M Edmondson, A Lawrence, R Luck, D Watson* (32); **(SA)** Women and Children's Hospital, *P Ashwood, C Crowther, D Gagliardi, L Simmonds* (103); **(TAS)** Launceston General Hospital, *A Dennis, E Fisher, M Parr* (27); North Western Regional Hospital, *B Dudfield, M Saunders* (2); **(VIC)** Monash Medical Centre, *J Mockler, E Wallace* (26); Royal Women's Hospital Melbourne, *S Cole, S Kane* (17); **(WA)** King Edward Memorial Hospital, *K Bosel, J Henderson, J McFarlane, N Pental, C Pennell, P Tan* (93); **BRAZIL (3):** Hospital Universitario Antonio Pedro, *Renato Sá* (3); **EGYPT (13):** Assiut University, *H Hamed, A Makhlouf* (13); **NEW ZEALAND (91):** Auckland City Hospital, *D Eaglen, K Groom, H Hauch* (13); Christchurch Women's Hospital, *D Leishman, B Pullar, R Reid*, (45); Dunedin Hospital, *S Fleming, H Paterson* (2); Middlemore Hospital, *G Parry* (10); Palmerston North Hospital, *K Gillies, N Shehata, R Chinoy* (21); **NORWAY (23):** *T Eggebø, B Esk* (23); **POLAND (11):** University of Medical Sciences, *G Bręborowicz, A Dera-Szymanska* (11); **ROMANIA (33):** University of Medicine Cluj, *A Cornea, I Frunzuc, C Mironiuc, O Pop, A Postole, F Stamatian* (33); **SOUTH AFRICA (56):** Stellenbosch University and Tygerberg Hospital, *D Hall, E Van Papendorp* (56); **UNITED KINGDOM (398):** Bradford Royal Infirmary, *G Butterfield, D Farrar, T Germaine, A Halford, V Jones, R Palethorpe, J Syson, D Tuffnell* (57); Chesterfield Royal Hospital, *J Cresswell, M Kelly-Baxter, L Underwood* (14); Countess of Chester Hospital, *N Kearsley, S Wood* (9); Cumberland Infirmary, *A McSkeane, A Wijesiriwardana* (6); Derriford Hospital, *T Asmussen, H Hollands, J Watson* (12); Diana, Princess of Wales Hospital, *H Gallagher, M Manohar, M Singh* (11); Gloucester Royal Hospital, *E Beach, M James, E Sonmezer* (8); King's Mill Hospital, *S Britt, Z Spendlove, S Ward* (17); Leighton Hospital, *J Brown, S Cunningham, C Dixon* (11); Ninewells Hospital, *M Macleod, G Mires* (18); Norfolk & Norwich University Hospital, *M Cameron, F Fraser, K Hargreaves, K Kardtomeikel* (17); Nottingham City Hospital, *J Fisher, N Grace, A Molnar, J Thornton* (41); Pilgrim Hospital, *S Ikhenia, S Molsher* (3); Queen Alexandra Hospital, *E Jenkins, M Salloum* (21); Queen's Medical Centre, *Y Davis, Y Gunn, J Thornton* (31); Royal Cornwall Hospital, *K Holland, H Probert, K Watkins* (18); Royal Devon & Exeter Hospital, *M Culverwell, K Brown, J Halpin, T Kay* (9); Royal Infirmary Edinburgh, *C Chiswick, R Hughes, Z Jones, A Keely, L Stirrat, V Sivalingam* (28); Sunderland Royal Hospital, *H Cameron, K Hinshaw, E Walton* (36); University of Coventry and Warwickshire, *J Duffy, J Findlay, M Kuca, J Woodman* (13); Warwick Hospital, *Z D'Souza, R Gabriel, A Guy, O Sorinola* (8); West Cumberland Hospital, *S Bober, E Simcock* (5); Whiston Hospital, *C Cunningham, C Nwosu* (5); **URUGUAY (28):** Perreira Rossell Hospital, *J Alonso, A Austt* (28)

Special acknowledgements: Bithi Roy (help with sepsis adjudication), Kate Levett (original trial coordinator)